DK1587957T3 - Genekspressionsmarkør til prognose af brystkræft - Google Patents

Genekspressionsmarkør til prognose af brystkræft

Info

Publication number
DK1587957T3
DK1587957T3 DK04702177.9T DK04702177T DK1587957T3 DK 1587957 T3 DK1587957 T3 DK 1587957T3 DK 04702177 T DK04702177 T DK 04702177T DK 1587957 T3 DK1587957 T3 DK 1587957T3
Authority
DK
Denmark
Prior art keywords
breast cancer
gene expression
cancer prognosis
expression marker
prognosis
Prior art date
Application number
DK04702177.9T
Other languages
English (en)
Inventor
Melody A Cobleigh
Joffre B Baker
Maureen T Cronin
Steve Shak
Original Assignee
Genomic Health Inc
Univ Rush Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32771871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1587957(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genomic Health Inc, Univ Rush Medical Center filed Critical Genomic Health Inc
Application granted granted Critical
Publication of DK1587957T3 publication Critical patent/DK1587957T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Motor Power Transmission Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
DK04702177.9T 2003-01-15 2004-01-14 Genekspressionsmarkør til prognose af brystkræft DK1587957T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44086103P 2003-01-15 2003-01-15
PCT/US2004/000985 WO2004065583A2 (en) 2003-01-15 2004-01-14 Gene expression markers for breast cancer prognosis

Publications (1)

Publication Number Publication Date
DK1587957T3 true DK1587957T3 (da) 2010-09-27

Family

ID=32771871

Family Applications (3)

Application Number Title Priority Date Filing Date
DK10162868.3T DK2230319T3 (da) 2003-01-15 2004-01-14 Genekspressionsmarkører til brystcancerprognose
DK04702177.9T DK1587957T3 (da) 2003-01-15 2004-01-14 Genekspressionsmarkør til prognose af brystkræft
DK15190640.1T DK3059322T3 (da) 2003-01-15 2004-01-14 Genekspressionsmarkører for brystcancerprognose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10162868.3T DK2230319T3 (da) 2003-01-15 2004-01-14 Genekspressionsmarkører til brystcancerprognose

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15190640.1T DK3059322T3 (da) 2003-01-15 2004-01-14 Genekspressionsmarkører for brystcancerprognose

Country Status (11)

Country Link
US (7) US20040231909A1 (da)
EP (4) EP3059322B1 (da)
JP (1) JP4723472B2 (da)
AT (1) ATE470723T1 (da)
AU (2) AU2004205878B2 (da)
CA (5) CA2829472C (da)
DE (1) DE602004027600D1 (da)
DK (3) DK2230319T3 (da)
ES (3) ES2346967T3 (da)
HK (1) HK1148783A1 (da)
WO (1) WO2004065583A2 (da)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
AU2002361784A1 (en) * 2001-12-20 2003-07-09 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
ATE529535T1 (de) * 2002-03-13 2011-11-15 Genomic Health Inc Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
ES2690168T3 (es) * 2003-06-24 2018-11-19 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
EP1644858B1 (en) * 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
DK2163650T3 (da) * 2004-04-09 2015-11-02 Genomic Health Inc Genekspressionsmarkører til forudsigelse af respons på kemoterapi
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
EP1781814B3 (en) * 2004-08-10 2011-08-31 Cardiff Biologicals Limited Methods and kit for the prognosis of breast cancer
KR20070068401A (ko) * 2004-09-22 2007-06-29 트리패스 이미징, 인코포레이티드 암의 예후에 대한 마커 후보의 분석 및 최적화를 위한 방법및 컴퓨터 프로그램 제품
US8065093B2 (en) 2004-10-06 2011-11-22 Agency For Science, Technology, And Research Methods, systems, and compositions for classification, prognosis, and diagnosis of cancers
JP4939425B2 (ja) * 2004-11-05 2012-05-23 ジェノミック ヘルス， インコーポレイテッド 乳癌の治療反応の予後および予測の分子指標
WO2006052862A1 (en) * 2004-11-05 2006-05-18 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
CN101115849A (zh) * 2004-12-07 2008-01-30 健泰科生物技术公司 选择her抑制剂疗法的患者
KR20170134771A (ko) 2005-01-21 2017-12-06 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
UA95902C2 (ru) 2005-02-23 2011-09-26 Дженентек, Инк. Способ увеличения времени развития заболевания или выживаемости у раковых пациентов
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US20080275652A1 (en) * 2005-05-13 2008-11-06 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
JP2009505658A (ja) * 2005-08-24 2009-02-12 ブリストル−マイヤーズ スクイブ カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
CA2628255C (en) 2005-10-31 2016-04-19 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1946118A4 (en) * 2005-11-10 2009-01-21 Aurelium Biopharma Inc TISSUE DIAGNOSIS OF BREAST CANCER
TW200731980A (en) * 2005-12-29 2007-09-01 Alcon Mfg Ltd RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis
WO2007123772A2 (en) 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
EP2390360A1 (en) * 2006-06-02 2011-11-30 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the IDO1 gene
WO2008063521A2 (en) * 2006-11-13 2008-05-29 The General Hospital Corporation Gene-based clinical scoring system
EP2106439B1 (en) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
ES2477497T3 (es) 2007-03-02 2014-07-17 Genentech, Inc. Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
WO2008150512A2 (en) * 2007-06-04 2008-12-11 University Of Louisville Research Foundation, Inc. Methods for identifying an increased likelihood of recurrence of breast cancer
EP2171090B1 (en) 2007-06-08 2013-04-03 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) * 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2191020A2 (en) * 2007-08-16 2010-06-02 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
GB0720113D0 (en) * 2007-10-15 2007-11-28 Cambridge Cancer Diagnostics L Diagnostic, prognostic and predictive testing for cancer
WO2009067655A2 (en) * 2007-11-21 2009-05-28 University Of Florida Research Foundation, Inc. Methods of feature selection through local learning; breast and prostate cancer prognostic markers
EP2065475A1 (en) * 2007-11-30 2009-06-03 Siemens Healthcare Diagnostics GmbH Method for therapy prediction in tumors having irregularities in the expression of at least one VEGF ligand and/or at least one ErbB-receptor
US20110130296A1 (en) * 2008-03-14 2011-06-02 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2012006632A2 (en) 2010-07-09 2012-01-12 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
US20110195995A1 (en) * 2008-10-14 2011-08-11 Wittliff James L Methods of Optimizing Treatment of Estrogen-Receptor Positive Breast Cancers
GB0821787D0 (en) * 2008-12-01 2009-01-07 Univ Ulster A genomic-based method of stratifying breast cancer patients
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US20120225789A1 (en) * 2009-05-29 2012-09-06 Baylor College Of Medicine Dna repair or brca1-like gene signature
JP5705836B2 (ja) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
EP2275569A1 (en) * 2009-07-17 2011-01-19 Centre Leon Berard ZNF217 a new prognostic and predictive biomarker of recurrent, invasive and metastatic phenotypes in cancer
GB0917457D0 (en) * 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
EP2504451B1 (en) * 2009-11-23 2019-06-05 Genomic Health, Inc. Methods to predict clinical outcome of cancer
WO2011088137A2 (en) * 2010-01-12 2011-07-21 H. Lee Moffitt Cancer Center & Research Institute Bad pathway gene signature
US20130143753A1 (en) * 2010-03-01 2013-06-06 Adelbio Methods for predicting outcome of breast cancer, and/or risk of relapse, response or survival of a patient suffering therefrom
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
JP2013535514A (ja) 2010-08-13 2013-09-12 エイルロン セラピューティクス，インコーポレイテッド ペプチド模倣大環状分子
US20120040861A1 (en) 2010-08-13 2012-02-16 Somalogic, Inc. Pancreatic Cancer Biomarkers and Uses Thereof
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
CA2818890C (en) 2010-11-23 2022-07-12 Krisani Biosciences (P) Ltd Method and system for prognosis and treatment of diseases using portfolio of genes
WO2012109233A2 (en) * 2011-02-07 2012-08-16 Board Of Regents, The University Of Texas System Methods for predicting recurrence risk in breast cancer patients
MX358886B (es) 2011-10-18 2018-08-31 Aileron Therapeutics Inc Macrociclos peptidomimeticos.
JP6147755B2 (ja) * 2011-11-08 2017-06-14 ジェノミック ヘルス， インコーポレイテッド 乳癌の予後を予測する方法
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
CN108912211A (zh) 2012-02-15 2018-11-30 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
WO2013170174A1 (en) 2012-05-10 2013-11-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of diagnosing, treating and determining progression and survival of cancer cells using bcl-2 antagonist of cell death (bad) pathway gene signature
US9890430B2 (en) 2012-06-12 2018-02-13 Washington University Copy number aberration driven endocrine response gene signature
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
EP4190918A1 (en) 2012-11-16 2023-06-07 Myriad Genetics, Inc. Gene signatures for cancer prognosis
MX363188B (es) 2012-11-30 2019-03-13 Hoffmann La Roche Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
US20150352193A1 (en) 2013-01-18 2015-12-10 Ellis Kline Selective glycosidase regimen for immune programming and treatment of cancer
CN104981697B (zh) 2013-02-11 2017-08-04 英丘伦有限责任公司 促染色质转录复合物(fact)在癌症中的用途
CN103465779B (zh) * 2013-09-17 2015-12-09 哈尔滨工程大学 双引擎全向四驱行进机构
CN103558383B (zh) * 2013-10-28 2015-11-18 深圳市第二人民医院 Aldh2基因在检测上尿路上皮癌中的应用
CN103558382B (zh) * 2013-10-28 2015-11-18 深圳市第二人民医院 Ccne1基因在检测上尿路上皮癌中的应用
KR20150088433A (ko) 2014-01-24 2015-08-03 삼성전자주식회사 c-Met 저해제의 효능 예측을 위한 바이오마커 TFF1
WO2015175692A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2016025785A1 (en) * 2014-08-15 2016-02-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for characterizing cancer
US10905739B2 (en) 2014-09-24 2021-02-02 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3210143B1 (en) 2014-10-24 2020-12-09 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
CA2965442A1 (en) 2014-10-24 2016-04-28 Koninklijke Philips N.V. Assessment of tgf-b cellular signaling pathway activity using mathematical modelling of target gene expression
BR112017007962A2 (pt) 2014-10-24 2018-01-23 Koninklijke Philips Nv método implementado por computador, aparelho, mídia de armazenamento, programa de computador, kit, e, uso do kit
CA2979847A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3073268A1 (en) * 2015-03-27 2016-09-28 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Biomarker panel for diagnosing cancer
ES2861400T3 (es) 2015-08-14 2021-10-06 Koninklijke Philips Nv Evaluación de la actividad de la ruta de señalización celular de NFkB usando modelos matemáticos de la expresión de genes diana
CN107058523A (zh) * 2017-03-21 2017-08-18 温州迪安医学检验所有限公司 一种乳腺癌复发风险评估21基因检测引物及其应用
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
CN110045120A (zh) * 2018-01-15 2019-07-23 长庚医疗财团法人基隆长庚纪念医院 检测生物样品中wisp1的浓度在制备用于乳癌筛检及侦测复发的检测试剂盒及其应用
WO2020013355A1 (ko) * 2018-07-10 2020-01-16 서울대학교산학협력단 악성 엽상종 예후 예측용 조성물 및 이를 포함하는 키트
WO2021030460A1 (en) * 2019-08-12 2021-02-18 Baylor College Of Medicine Proteogenomic methods for diagnosing cancer
CN113862363A (zh) * 2021-10-27 2021-12-31 中山大学附属第一医院 免疫相关基因在乳腺癌预后的试剂盒和系统中的应用
CN114480650A (zh) * 2022-02-08 2022-05-13 深圳市陆为生物技术有限公司 一种预测三阴乳腺癌临床预后复发风险的标志物及模型

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE56509B1 (en) 1982-11-04 1991-08-28 Univ California Methods for oncogenic detection
USRE35491E (en) 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4699877A (en) 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5922855A (en) * 1993-12-17 1999-07-13 Oregon Health Sciences University Mammalian DNA mismatch repair genes MLH1 and PMS1
US6037134A (en) * 1994-03-07 2000-03-14 New York University Medical Center Methods that detect compounds that disrupt receptor tyrosine kinase/GRB-7 complexes
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5858678A (en) 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US6218529B1 (en) * 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2262403C (en) 1995-07-31 2011-09-20 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
KR100459052B1 (ko) 1995-12-18 2005-01-15 서젠, 인크. Aur-1및(또는)aur-2관련질병의진단및치료
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US5670325A (en) 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US5821082A (en) 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US5928870A (en) 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6020137A (en) 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6100029A (en) 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US6146828A (en) 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6143529A (en) 1996-08-14 2000-11-07 Exact Laboratories, Inc. Methods for improving sensitivity and specificity of screening assays
US5952178A (en) 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US5861278A (en) 1996-11-01 1999-01-19 Genetics Institute, Inc. HNF3δ compositions
ATE414149T1 (de) 1996-11-20 2008-11-15 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
US5830665A (en) 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
US6033893A (en) 1997-06-26 2000-03-07 Incyte Pharmaceuticals, Inc. Human cathepsin
WO1999002714A1 (en) 1997-07-07 1999-01-21 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
DE69836823D1 (de) * 1997-10-21 2007-02-15 Univ Glasgow Jmy, mit-aktivator für p300/cbp, dafür kodierendenucleinsäure und deren verwendungen
EP1066517B1 (en) * 1998-02-25 2006-11-29 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Cellular arrays for rapid molecular profiling
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
WO1999064627A2 (en) 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
JP2003528564A (ja) 1998-06-06 2003-09-30 ジェノスティック ファーマ リミテッド 遺伝的プロファイリングに使用するプローブ
US6696558B2 (en) 1998-09-09 2004-02-24 The Burnham Institute Bag proteins and nucleic acid molecules encoding them
EP1115737A4 (en) 1998-09-23 2004-11-24 Cleveland Clinic Foundation NEW GENES STIMULATED OR REPRESSED BY INTERFERON
US9534254B1 (en) * 1999-02-02 2017-01-03 Abbott Molecular Inc. Patient stratification for cancer therapy based on genomic DNA microarray analysis
US6251601B1 (en) 1999-02-02 2001-06-26 Vysis, Inc. Simultaneous measurement of gene expression and genomic abnormalities using nucleic acid microarrays
WO2000050595A2 (en) 1999-02-25 2000-08-31 Ivan Gout Nucleic acid molecules associated with melanoma and thyroid tumors
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US20020039764A1 (en) 1999-03-12 2002-04-04 Rosen Craig A. Nucleic, acids, proteins, and antibodies
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6326148B1 (en) 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
US6710170B2 (en) 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
WO2001025250A1 (en) 1999-10-06 2001-04-12 The Regents Of The University Of California Differentially expressed genes associated with her-2/neu overexpression
EP1661996A1 (en) 1999-12-01 2006-05-31 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6750013B2 (en) 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US6248535B1 (en) 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
WO2001051664A2 (en) * 2000-01-12 2001-07-19 Dana-Farber Cancer Institute, Inc. Method of detecting and characterizing a neoplasm
WO2001051661A2 (en) 2000-01-13 2001-07-19 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
US6322986B1 (en) 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
CA2398107C (en) 2000-01-28 2013-11-19 Althea Technologies, Inc. Methods for analysis of gene expression
CA2395827A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030165831A1 (en) 2000-03-21 2003-09-04 John Lee Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
WO2001075162A2 (en) 2000-03-31 2001-10-11 University Of Louisville Research Foundation, Inc. Microarrays to screen regulatory genes
WO2002000677A1 (en) 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030165952A1 (en) 2000-07-21 2003-09-04 Sten Linnarsson Method and an alggorithm for mrna expression analysis
AU2001277202A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ras/rerg protein and related reagents and methods of use thereof
US7118853B2 (en) 2000-07-26 2006-10-10 Applied Genomics, Inc. Methods of classifying, diagnosing, stratifying and treating cancer patients and their tumors
WO2002008260A2 (en) 2000-07-26 2002-01-31 Stanford University Bstp-ecg1 protein and related reagents and methods of use thereof
WO2002010436A2 (en) * 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US6378397B1 (en) * 2000-10-25 2002-04-30 Jenn Jianq Co., Ltd. Differential gearing device
US6582919B2 (en) 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US6602670B2 (en) 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
WO2002046467A2 (en) * 2000-12-08 2002-06-13 Ipsogen Gene expression profiling of primary breast carcinomas using arrays of candidate genes
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
CN1636139A (zh) 2001-01-12 2005-07-06 耶鲁大学 癌症病人的生物液体中存活素的检测
US7776518B2 (en) 2001-01-12 2010-08-17 Yale University Detection of survivin in the biological fluids of cancer patients
AU2002245317A1 (en) 2001-01-24 2002-08-06 Protein Design Labs Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
AU2002253878A1 (en) * 2001-01-25 2002-08-06 Gene Logic, Inc. Gene expression profiles in breast tissue
NZ528205A (en) 2001-03-12 2006-09-29 Monogen Inc Cell-based detection and differentiation of disease status in a cytological sample using a panel comprising a plurality of probes
US20050260572A1 (en) 2001-03-14 2005-11-24 Kikuya Kato Method of predicting cancer
US6655515B2 (en) * 2001-05-24 2003-12-02 Tecumseh Products Company Modular bi-directional overrunning wheel clutch
WO2002103320A2 (en) 2001-06-18 2002-12-27 Rosetta Inpharmatics, Inc. Diagnosis and prognosis of breast cancer patients
US7125680B2 (en) 2001-07-27 2006-10-24 The Regents Of The University Of California Methods and materials for characterizing and modulating interaction between heregulin and HER3
US6898531B2 (en) * 2001-09-05 2005-05-24 Perlegen Sciences, Inc. Algorithms for selection of primer pairs
EP1444361A4 (en) 2001-09-28 2006-12-27 Whitehead Biomedical Inst CLASSIFICATION OF LUNG CARCINOMAS BY GENE EXPRESSION ANALYSIS
EP1451340B1 (en) 2001-11-09 2014-01-08 Life Technologies Corporation Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
ATE529535T1 (de) 2002-03-13 2011-11-15 Genomic Health Inc Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe
CA2480635A1 (en) 2002-03-28 2003-10-09 Allen D. Delaney Cancer associated protein kinases and their uses
EP1365034A3 (en) 2002-05-21 2004-02-18 Bayer HealthCare AG Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
EP2284266B1 (en) * 2002-11-14 2013-11-06 Thermo Fisher Scientific Biosciences Inc. siRNA targeting tp53
CA2511907A1 (en) * 2003-01-06 2004-07-22 Wyeth Compositions and methods for diagnosing and treating colon cancers
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
DE602004017426D1 (de) 2003-02-20 2008-12-11 Genomic Health Inc Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression
AU2004248120B2 (en) 2003-05-28 2009-04-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
ES2690168T3 (es) * 2003-06-24 2018-11-19 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
EP1644858B1 (en) 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
DK2163650T3 (da) 2004-04-09 2015-11-02 Genomic Health Inc Genekspressionsmarkører til forudsigelse af respons på kemoterapi
JP4939425B2 (ja) 2004-11-05 2012-05-23 ジェノミック ヘルス， インコーポレイテッド 乳癌の治療反応の予後および予測の分子指標
WO2006052862A1 (en) 2004-11-05 2006-05-18 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
CA2620936A1 (en) 2005-09-01 2007-03-08 Precision Therapeutics, Inc. Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
WO2007123772A2 (en) 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
EP2191020A2 (en) 2007-08-16 2010-06-02 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
US20090311702A1 (en) 2008-05-12 2009-12-17 Steve Shak Tests to predict responsiveness of cancer patients to chemotherapy treatment options
BRPI1013997A2 (pt) 2009-07-02 2016-04-05 Basf Se método para a produção de uma dispersão co-aglomerada, dispersão aquosa, polímero espumado, método para a produção de um polímero espumado, adesivo à base de látex, método de adesão de um substrato a uma superfície, composição asfáltica modificada.
EP2504451B1 (en) 2009-11-23 2019-06-05 Genomic Health, Inc. Methods to predict clinical outcome of cancer

Also Published As

Publication number Publication date
EP2230319B1 (en) 2015-10-21
EP1587957A2 (en) 2005-10-26
US20100222229A1 (en) 2010-09-02
JP4723472B2 (ja) 2011-07-13
DE602004027600D1 (de) 2010-07-22
CA2513117C (en) 2014-02-25
US20180230548A1 (en) 2018-08-16
AU2004205878B2 (en) 2009-08-27
WO2004065583A3 (en) 2005-03-03
DK2230319T3 (da) 2016-01-25
AU2009238287A1 (en) 2009-12-03
US20110312532A1 (en) 2011-12-22
EP3059322B1 (en) 2019-04-10
JP2006516897A (ja) 2006-07-13
CA2829477A1 (en) 2004-08-05
CA2829476C (en) 2018-07-10
ES2346967T3 (es) 2010-10-22
US20120225433A1 (en) 2012-09-06
EP2230319A3 (en) 2011-01-12
US9944990B2 (en) 2018-04-17
EP2230319A2 (en) 2010-09-22
US7569345B2 (en) 2009-08-04
CA2513117A1 (en) 2004-08-05
CA2829472C (en) 2018-08-14
ATE470723T1 (de) 2010-06-15
AU2004205878A8 (en) 2004-08-05
CA2829472A1 (en) 2004-08-05
EP2230318A1 (en) 2010-09-22
CA2829476A1 (en) 2004-08-05
US20040209290A1 (en) 2004-10-21
DK3059322T3 (da) 2019-05-06
US8034565B2 (en) 2011-10-11
EP3059322A1 (en) 2016-08-24
ES2725892T3 (es) 2019-09-30
ES2561179T3 (es) 2016-02-24
EP1587957B1 (en) 2010-06-09
CA2829477C (en) 2018-07-10
CA3013889A1 (en) 2004-08-05
AU2004205878A1 (en) 2004-08-05
US20140287421A1 (en) 2014-09-25
US8206919B2 (en) 2012-06-26
US8741605B2 (en) 2014-06-03
HK1148783A1 (zh) 2011-09-16
US20040231909A1 (en) 2004-11-25
US11220715B2 (en) 2022-01-11
WO2004065583A2 (en) 2004-08-05
AU2009238287B2 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
DK1587957T3 (da) Genekspressionsmarkør til prognose af brystkræft
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
DK1765391T3 (da) Bakterielle præparater til behandlingen af cancer
WO2008008430A3 (en) Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
CY1126007T1 (el) Προαγωγεις αποπτωσης
FI20060154A (fi) Neurogeneratiivisten tilojen hoito
DK1755671T3 (da) Terapi af platinresistent cancer
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
DE60234439D1 (de) Stent zur ableitung von körperflüssigkeiten
DE502007002289D1 (de) Methacrylatharze zur herstellung von fahrbahnmarkierungen
DK1716119T3 (da) Analoger af benzoquinonholdige ansamyciner til behandling af cancer
ATE470672T1 (de) Verwendung von cupredoxin-proteine für krebstherapie
HK1145342A1 (en) Prognosis prediction for melanoma cancer
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602006013109D1 (de) Markerprotein zur verwendung bei der diagnose von bauchspeicheldrüsenkrebs
NO20053903D0 (no) Nukleotidlipidesterderivater.
TW200605885A (en) Multicyclic lonidamine analogs
DE60317606D1 (de) Marker für Brustkrebsprognose
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme
DE60325194D1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
ATE549026T1 (de) Verwendung von pinitol zur behandlung von leberkrankheiten in säugetieren
BRPI0415355A (pt) triarilimidazóis
DE60328516D1 (de) Thia-epothilon derivate zur krebsbehandlung